Home » , » Raffles Medical Group - Upgrade to buy on valuation grounds‏

Raffles Medical Group - Upgrade to buy on valuation grounds‏

Shared By Stock Fanatic on Monday, November 23, 2015 | 23.11.15

■ Share price declined post results

■ No change to estimates

■ Opportunity to accumulate shares

Management looking to improve efficiency
Raffles Medical Group’s share price has since tumbled 16.6% from its 52-week high of S$4.99 in July, or by 5.2% post 3Q results. The marginal 1.2% increase in 3Q PATMI was a tad below our expectations, and this was due to higher staff costs, depreciation costs and operating lease expenses. But we acknowledge that this is inevitable, given the group’s capacity expansion plans. These plans include the new medical centre at Shaw Centre that was opened in 2H15 as well as the Holland Village project. Nurses and staffs have to be trained before the new centres are opened, thus expenses have to be incurred before any meaningful revenue contribution. 4Q should see some revenue contribution from the Shaw Centre facility; and it is usually their strongest quarter. Looking ahead, we remain cognizant of the cost pressures from all fronts, while management is focused on striving to achieve higher operational efficiency.

Not all is lost despite risk of flagging medical tourism
Although the group had witnessed a lower volume of foreign patients from countries like Indonesia and Russia, we understand that they saw higher intensity cases such as their bone marrow transplant programme. Thus, while there is the risk of some patients choosing other hospitals for cheaper cost of treatment, we note that RMG still serves a premium segment of patients, and such specialized treatments enable them to remain a strong contender against their regional competitors. Nonetheless, diversification also remains important, and RFMD has been doing so with its new centre in Japan and the acquisition of International SOS (MC Holdings) Pte Ltd.

Technical Analysis
Daily Chart
Not expensive relative to peers
We previously noted that longer-term investors could look to accumulate the group’s shares below S$4.36, thus we think value has re-emerged with the recent share price correction. Its current valuation at 30.4x FY16F earnings does not look expensive relative to their healthcare peers; hence we upgrade the stock from hold to BUY, with no change to our estimates and fair value of S$4.59. (Read Report)

Source : OCBC Investment Research

Posted on Monday, November 23, 2015 | 23.11.15
With No comments

Join Me On: Facebook | Twitter | Google Plus ::: Thank you for visiting ! :::
Some of the photos shown in this blog are randomly sourced from the Public Domain. If there is an infringement in the copyright of the photos; kindly inform us and it will be removed immediately. Thank you for your kind understanding.
Share this article :

Post a Comment

Modified by : Stockfanatic
Copyright © 2008 - 2018. Singapore Stock Market News - All Rights Reserved
Template Created by Creating Website Published by Mas Template
Proudly powered by Blogger
Related Posts with Thumbnails